{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:42:33Z","timestamp":1792629753384,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastric immunoglobulin G4-related disease (IgG4-RD) is exceedingly rare, with fewer than 50 cases reported worldwide. Its mass-forming presentation frequently mimics malignancy, leading to high rates of unnecessary surgical resection. Inebilizumab, a CD19-directed monoclonal antibody and the first FDA-approved therapy for IgG4-RD, has not previously been described in gastric IgG4-RD. We report the first case of mass-forming gastric IgG4-RD treated with inebilizumab, achieving clinical, endoscopic, and histologic remission without surgical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 52-year-old man with chronic hypereosinophilia, nonischemic cardiomyopathy, and multisystem inflammatory disease presented with symptomatic anemia and a 2\u00a0cm gastric antral mass identified on CT imaging. Endoscopy revealed an antral mass, highly suspicious for malignancy. Initial biopsies showed\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      associated chronic active gastritis without definitive malignancy. Repeat sampling after\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication demonstrated dense transmural lymphoplasmacytic and eosinophilic infiltration with 225 IgG4\u207a plasma cells per high-power field, an IgG4\/IgG ratio of 37.5%, and a markedly elevated serum IgG4 of 1,245\u00a0mg\/dL, establishing the diagnosis of gastric IgG4-RD. Concurrent lung biopsy confirmed multisystem involvement. The patient was initiated on inebilizumab. Within six weeks, follow-up endoscopy demonstrated significant resolution of the gastric mass with histologic remission (IgG4\/IgG ratio\u2009&lt;\u200910%), and six-month follow-up revealed near-complete resolution of the gastric abnormalities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrates that CD19-targeted B-cell depletion with inebilizumab can induce rapid, profound remission in gastric IgG4-RD, obviating the need for gastrectomy and chronic glucocorticoid therapy. These findings support early consideration of IgG4-RD in the differential diagnosis of mass-forming gastric lesions and highlight the transformative potential of mechanism-based therapy in this diagnostically challenging condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-05139-z","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:55:11Z","timestamp":1784984111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dramatic regression of mass-forming gastric IgG4-related disease with inebilizumab: a case report"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1830-8145","authenticated-orcid":false,"given":"Rami","family":"Jadallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikrant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Notta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Wasay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Eberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker","family":"Barham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"4","key":"5139_CR1","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2018.06.082","volume":"155","author":"K Miyabe","year":"2018","unstructured":"Miyabe K, et al. Gastrointestinal and extra-intestinal manifestations of IgG4-related disease. Gastroenterology. 2018;155(4):990-1003.e1.","journal-title":"Gastroenterology"},{"issue":"6","key":"5139_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539\u201351.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"5139_CR3","doi-asserted-by":"publisher","first-page":"iii123","DOI":"10.1093\/rheumatology\/kez667","volume":"59","author":"F Maritati","year":"2020","unstructured":"Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology (Oxford). 2020;59(Suppl 3):iii123\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5139_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-021-00529-y","volume":"19","author":"JM L\u00f6hr","year":"2022","unstructured":"L\u00f6hr JM, et al. IgG4-related diseases of the digestive tract. Nat Rev Gastroenterol Hepatol. 2022;19(3):185\u201397.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"5139_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","volume":"25","author":"V Deshpande","year":"2012","unstructured":"Deshpande V, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181\u201392.","journal-title":"Mod Pathol"},{"key":"5139_CR6","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fimmu.2025.1584107","volume":"16","author":"J Motor","year":"2025","unstructured":"Motor J, et al. IgG4-related disease - focus on digestive system involvement. Front Immunol. 2025;16:2025.","journal-title":"Front Immunol"},{"issue":"1","key":"5139_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00535-025-02307-y","volume":"61","author":"A Masuda","year":"2026","unstructured":"Masuda A, et al. Clinical manifestations of immunoglobulin G4-related gastrointestinal disease: a nationwide multicenter retrospective study. J Gastroenterol. 2026;61(1):16\u201326.","journal-title":"J Gastroenterol"},{"issue":"10","key":"5139_CR8","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1111\/jgh.15980","volume":"37","author":"H Sawada","year":"2022","unstructured":"Sawada H, et al. Clinicopathological characteristics of gastric IgG4-related disease: systematic scoping review. J Gastroenterol Hepatol. 2022;37(10):1865\u201372.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"5139_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14397595.2016.1209819","volume":"29","author":"D Inoue","year":"2019","unstructured":"Inoue D, et al. Imaging and pathological features of gastric lesion of immunoglobulin G4-related disease: a case report and review of the recent literature. Mod Rheumatol. 2019;29(2):377\u201382.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"5139_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1159\/000501513","volume":"101","author":"S Khan","year":"2020","unstructured":"Khan S, et al. Immunoglobulin G4-related disease manifesting as isolated, typical, and nontypical gastroesophageal lesion: a research of literature review. Digestion. 2020;101(5):506\u201321.","journal-title":"Digestion"},{"issue":"7","key":"5139_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00535-017-1420-4","volume":"53","author":"K Notohara","year":"2018","unstructured":"Notohara K, et al. Gastrointestinal manifestation of immunoglobulin G4-related disease: clarification through a multicenter survey. J Gastroenterol. 2018;53(7):845\u201353.","journal-title":"J Gastroenterol"},{"issue":"2","key":"5139_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/pin.13059","volume":"71","author":"K Uchino","year":"2021","unstructured":"Uchino K, et al. Utility of gastric biopsy in diagnosing IgG4-related gastrointestinal disease. Pathol Int. 2021;71(2):124\u201334.","journal-title":"Pathol Int"},{"issue":"5","key":"5139_CR13","first-page":"1038","volume":"40","author":"B Ming","year":"2022","unstructured":"Ming B, Zhong J, Dong L. Role of eosinophilia in IgG4-related disease. Clin Exp Rheumatol. 2022;40(5):1038\u201344.","journal-title":"Clin Exp Rheumatol"},{"key":"5139_CR14","doi-asserted-by":"publisher","first-page":"105873","DOI":"10.1016\/j.humpath.2025.105873","volume":"163","author":"T Chen","year":"2025","unstructured":"Chen T, et al. IgG4-related disease of the tubular gastrointestinal tract: a rare cause of lymphoplasmacytosis, eosinophilia, and mass-forming lesions. Hum Pathol. 2025;163:105873.","journal-title":"Hum Pathol"},{"issue":"3","key":"5139_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.pan.2017.04.002","volume":"17","author":"EL Culver","year":"2017","unstructured":"Culver EL, et al. No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. Pancreatology. 2017;17(3):395\u2013402.","journal-title":"Pancreatology"},{"issue":"11","key":"5139_CR16","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.3748\/wjg.v21.i11.3429","volume":"21","author":"M Li","year":"2015","unstructured":"Li M, et al. Rare case of Helicobacter pylori-positive multiorgan IgG4-related disease and gastric cancer. World J Gastroenterol. 2015;21(11):3429\u201334.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5139_CR17","doi-asserted-by":"publisher","first-page":"103273","DOI":"10.1016\/j.autrev.2023.103273","volume":"22","author":"O Orozco-G\u00e1lvez","year":"2023","unstructured":"Orozco-G\u00e1lvez O, et al. Development of an algorithm for IgG4-related disease management. Autoimmun Rev. 2023;22(3):103273.","journal-title":"Autoimmun Rev"},{"key":"5139_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1146\/annurev-med-050219-034449","volume":"73","author":"G Katz","year":"2022","unstructured":"Katz G, Stone JH. Clinical perspectives on IgG4-related disease and its classification. Annu Rev Med. 2022;73:545\u201362.","journal-title":"Annu Rev Med"},{"key":"5139_CR19","doi-asserted-by":"publisher","first-page":"e950212","DOI":"10.12659\/MSM.950212","volume":"31","author":"DV Parums","year":"2025","unstructured":"Parums DV. IgG4-related disease: a review of persistent challenges in the pathogenesis, diagnosis, and approaches to treatment. Med Sci Monit. 2025;31:e950212.","journal-title":"Med Sci Monit"},{"issue":"5","key":"5139_CR20","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/rheumatology\/keae675","volume":"64","author":"M Colquhoun","year":"2025","unstructured":"Colquhoun M, et al. A protocol for targeted B-lymphocyte depletion for the treatment of IgG4-related disease. Rheumatology (Oxford). 2025;64(5):2847\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"5139_CR21","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","volume":"392","author":"JH Stone","year":"2025","unstructured":"Stone JH, et al. Inebilizumab for treatment of IgG4-related disease. N Engl J Med. 2025;392(12):1168\u201377.","journal-title":"N Engl J Med"},{"issue":"1","key":"5139_CR22","doi-asserted-by":"publisher","first-page":"16483","DOI":"10.1038\/s41598-019-52847-6","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang X, et al. Different clinical patterns of IgG4-RD patients with and without eosinophilia. Sci Rep. 2019;9(1):16483.","journal-title":"Sci Rep"},{"issue":"9","key":"5139_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cgh.2017.02.007","volume":"15","author":"EL Culver","year":"2017","unstructured":"Culver EL, et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin Gastroenterol Hepatol. 2017;15(9):1444-1452.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"5139_CR24","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1097\/RHU.0000000000001606","volume":"27","author":"Z Wu","year":"2021","unstructured":"Wu Z, et al. Elevated serum IgG4 was found in eosinophilic granulomatosis with polyangiitis. J Clin Rheumatol. 2021;27(8):e501\u20134.","journal-title":"J Clin Rheumatol"},{"key":"5139_CR25","doi-asserted-by":"publisher","unstructured":"Kubo S, et al. Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. RMD Open. 2022;8(1):e002086. https:\/\/doi.org\/10.1136\/rmdopen-2021-002086.","DOI":"10.1136\/rmdopen-2021-002086"},{"issue":"1","key":"5139_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000530373","volume":"17","author":"H Mohideen","year":"2023","unstructured":"Mohideen H, et al. Gastrointestinal eosinophilic granulomatosis with polyangiitis following a Clostridium difficile infection. Case Rep Gastroenterol. 2023;17(1):228\u201334.","journal-title":"Case Rep Gastroenterol"},{"issue":"1","key":"5139_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270\u201381.","journal-title":"Arthritis Rheum"},{"issue":"3 Suppl 82","key":"5139_CR28","first-page":"S41","volume":"32","author":"BM Sokolowska","year":"2014","unstructured":"Sokolowska BM, et al. ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S41\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5139_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/jcp-2023-209280","volume":"79","author":"A Nishikori","year":"2025","unstructured":"Nishikori A, et al. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): factors to differentiate from IgG4-related disease. J Clin Pathol. 2025;79(1):43\u20139.","journal-title":"J Clin Pathol"},{"issue":"1","key":"5139_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","volume":"72","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, et al. The 2019 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2020;72(1):7\u201319.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"5139_CR31","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00296-021-04946-9","volume":"42","author":"M Doumen","year":"2022","unstructured":"Doumen M, et al. Pericarditis as a manifestation of IgG4-related disease. Rheumatol Int. 2022;42(7):1287\u201395.","journal-title":"Rheumatol Int"},{"issue":"3","key":"5139_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1573403X15666190117101607","volume":"15","author":"A Fathala","year":"2019","unstructured":"Fathala A. Multimodalities imaging of immunoglobulin 4-related cardiovascular disorders. Curr Cardiol Rev. 2019;15(3):224\u20139.","journal-title":"Curr Cardiol Rev"},{"key":"5139_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/1756-0500-6-538","volume":"6","author":"J Rizkallah","year":"2013","unstructured":"Rizkallah J, et al. Eosinophilic myocarditis: two case reports and review of the literature. BMC Res Notes. 2013;6:538.","journal-title":"BMC Res Notes"},{"key":"#cr-split#-5139_CR34.1","unstructured":"U.S. National Library of Medicine. UPLIZNA (inebilizumab-cdon) injection. [Drug label \/ Prescribing information] 2025"},{"key":"#cr-split#-5139_CR34.2","unstructured":"Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=834db232-afb0-4dcf-93e0-009ce8245c20&utm. Cited 2026 24 February."},{"issue":"7","key":"5139_CR35","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688\u201399.","journal-title":"Arthritis Rheumatol"},{"key":"5139_CR36","doi-asserted-by":"publisher","unstructured":"Malfertheiner P, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022;71(9):1724\u201362. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","DOI":"10.1136\/gutjnl-2022-327745"},{"issue":"10206","key":"5139_CR37","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05139-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:08:03Z","timestamp":1792627683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05139-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5139"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05139-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report was reviewed and approved by the Institutional Review Board (IRB) of the University of Tennessee Health Science Center (IRB approval number: CR# 653). Written informed consent to participate was obtained from the patient prior to inclusion in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying clinical details, images, and identifying information. A copy of the signed written consent form is available for review by the Editor-in-Chief of this journal upon request.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"685"}}